We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Roses, whilst I agree with you on that front.
If the SA ethics committee is anything like ethics committees here in the UK, if payments to participants wasn't in the original submission, you would have to go back to the ethics committee for an amendment.
Depending on what timelines are like for amendments it might take longer to get the protocol amended and then start issuing payments to new recruits, than it would to recruit the full cohort of patients through the original route. Furthermore, here in the UK renumeration has to be an appropriate amount for the procedures/risk you are expecting a patient to go through. It's a balancing act because you obviously want people to come forward to participate and you do not want patients to be out of pocket because this would be self selecting for participants who could afford to attend clinic, take time off work etc, but you also do not want financial reinbursement to be of a level where you attract people from low income or impoverished backgrounds who are doing it for the finances rather than the science. (For those of you interested in this, there is a quite detailed information document on the HRA stance and ethics surrounding payment for participants in trials/research at https://s3.eu-west-2.amazonaws.com/www.hra.nhs.uk/media/documents/hra-guidance-payments-incentives-research.pdf)
Agree sicilian ken, we siply must have decided when micron surfaced to delay further recruitment for a period until more was known.
Expecting a bounce back today from early losses. IMHO
If the company wants to accelerate the recruitment, all they would need to do is pay a decent fee to the recruitees and they would fill it in no time.
A small amount of money goes a lot further in SA.
Just to put this into perspective, when the Covidity news that they had merely developed the vaccine was announced, stating they intended to put Covidity into trials in 2021 (which later happened), the share price shot up from 14p to 30p, before dropping back down to the 20-22p region.
We are now back to 17.75p mid, almost back to where we started, despite Covidity now being in trials, having been proven to be safe in 16 patients, and with partnership planned once the data comes out this half year.
Each one of these is massive progress over last year. And we also have SCIB1 first patient dosed, which we did not have then, and Modi-1 due to start trials this half too. Cash levels are very good with no need for dilution. We have also had a supportive board with a connected party buying when the sp fell below 19p.
All in all, I think the fall unjustified. I understand that people will drift out when there are delays, but these are small delays and with Covidity recruitment due to pick up as the RNS says, it won't be that long before we get a recruitment complete RNS from Covidity and the landscape will change in (in the grand scheme of things) very little time.
Chester
Brilliant timing for your post yesterday!
About the best pre figures post I've ever seen on LSE.
"I'm being very cautious with my expectation for tomorrow. ......"
Spot on!
Hi Chester,
""I'm being very cautious with my expectation for tomorrow. I have been guilty in the past of being far to optimistic when it wasn't justified, which comes across as either, over zealous or evangelical.|""|
Chester, speaking for myself I don|"t think you have ever been guilty of any of those things. You have always added to this BB in a pleasant, informative way and listed meticulously what news MIGHT or COULD be due. in the same manner as others and myself would say what COULD happen or more importantly what we HOPE might be the next news. I really don|"t accept that as being overly zealous or evangelical. It is then for us or me as an individual to decide what from the choices given is the most likely to occur and often I am reminded of a piece of news I had not thought of for a while before. i am sre without the onset of Covid a few things that you listed might well have occurred by now.
I notice a few of us are specifically using the word hope, as I did last week over a potential Diggle buy, as someone else did today without having to undergo 15 posts inquisition about their integrity.
With results due tomorrow it has always been my HOPE we have some good news to take away just the headline |"Scancell report record half year losses|" which a good update on the Covidity trial and any more patients dosed in our cancer trials will do. In the absence of that I am hoping Mondays fall takes that into account and tomorrow we can bounce back just a little bit more like today from Mondays mauling, which I didn|"t enjoy watching one iota.
So good luck to us all in the morning, and with the hope that there is enough there on the table for investors to feel now is a good time to add and let us settle at least back to 20/21.
Catch you tomorrow guys, fingers crossed and keep punching ATVB...............C7
Chester,
Your 13.21 is IMO precisely the way to look at Scancell now.
I firmly believe that SP wise it is far better to expect little and be pleasantly surprised, rather than to expect more than is realistic and be disappointed.
The latter situation has been the prevailing output from many BBs over the years and that has been so counter productive.
We as investors seem to be in the best place with Scancell that can be expected at the moment with a great deal of possible news to come.
When that might arrive is anybody's GUESS but applying your logic from your 13.21 is again IMO the most sensible course of action to take.
Then when (and if) we get the results we hope for maybe everyone can celebrate together rather than all trying to take credit for who's the "Cleverest" in anticipating the good news.
I think we can all accept that nobody can really claim to be the best if they've been trapped/invested without a break in here for the last ten years or so.
So Chester thankyou for your first paragraph in your 13.21 and your candour in writing it. I believe you have hit the nail firmly on the head! All credit to you.
AIMO
Hi C11
I'm being very cautious with my expectation for tomorrow. I have been guilty in the past of being far to optimistic when it wasn't justified, which comes across as either, over zealous or evangelical.
If the science over the next 6 / 12 months matches up to our long held expectations Scancell will become a well know and influential name in Immuno oncology and vaccines. These next steps, as the clinical data begins to emerge, are most crucial if our vision for Scancell has the chance of becoming reality.
Tick Tock....
Chester.
Hey Chester.
Whilst I agree something SP busting is unlikely, I am, reasonably I believe, hoping for something more than “fairly positive!” :-)
Tomorrows' Interim report should be fairly positive with expectations of what the company wants to achieve over the next 6 months. Anything above the standard mix of past and future reporting, for instance, The Modi Trial has already started would be surprising.
I'm expecting projections on when the Modi1 and Scib1 clinic's will be ready to dose the already selected patients, maybe an update on AvidiMab progress and of course, a timeline for reporting on the Covidity Safety and Immunogenicity.
Not SP busting news but a solid positive update. The level of Covidity's 'T' Cell and Antibody responses, will for now, have the main impact on the share price.
Chester.
Well said C11 ! Yes there were many more positives in Prof. Lindy's Oct update. Let's hope there's more. ATB
TF - surely no one is bothered by what Cliff said in Jan 21, when in Oct 21 Lindy gave this update:
"We have achieved a lot in this transformational year for Scancell; strengthening the Group's cash position and accelerating the progress of our novel cancer and COVID-19 vaccines into the clinic. We have recently initiated our COVIDITY programme, which aims to develop a next generation, DNA-based COVID-19 vaccine, which we believe may have advantages over current mRNA-based vaccines, and we look forward to reporting safety and immunogenicity data during H1 2022. We have also progressed development of Modi-1, the first candidate arising from our Moditope® platform, and look forward to the first patients being dosed in our Phase 1/2 clinical trial shortly. Additionally, we are advancing our unique pipeline of anti-TaG antibodies with the initial aim of generating early stage clinical data, either alone or in combination with strategic partners. I am excited at what the future holds for the Group and we look forward to making further progress over the coming year."
I think it’s any change in that, that we are hoping for. Material change over a re-write.
So do I Moonparty !
I see there's no luck with an RNS today BUT I confidently predict, there will be an RNS tomorrow, (wink).
Last year in the Interim report, Cliff Holloway said, "We continue to work towards developing an effective and differentiated vaccine against COVID-19, potentially active against new variants of the SARS-CoV-2 virus, whilst also making progress with our Moditope®, ImmunoBody® and AvidiMab™ platforms."
Of course that could be same again, but let's see what Prof. Lindy has for us in highlights and comments tomorrow. GLA
US markets actually ended up on the day, after being heavily down at London close. Also, it's the last day to place your bets before the interims.